Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases.

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. Abstract Text:

Charles H King,Anne-Marie Bertino,

The disability-adjusted life year (DALY) initially appeared attractive as a health metric in the Global Burden of Disease (GBD) program, as it purports to be a comprehensive health assessment that encompassed premature mortality, morbidity, impairment, and disability. It was originally thought that the DALY would be useful in policy settings, reflecting normative valuations as a standardized unit of ill health. However, the design of the DALY and its use in policy estimates contain inherent flaws that result in systematic undervaluation of the importance of chronic diseases, such as many of the neglected tropical diseases (NTDs), in world health. The conceptual design of the DALY comes out of a perspective largely focused on the individual risk rather than the ecology of disease, thus failing to acknowledge the implications of context on the burden of disease for the poor. It is nonrepresentative of the impact of poverty on disability, which results in the significant underestimation of disability weights for chronic diseases such as the NTDs. Finally, the application of the DALY in policy estimates does not account for the nonlinear effects of poverty in the cost-utility analysis of disease control, effectively discounting the utility of comprehensively treating NTDs. The present DALY framework needs to be substantially revised if the GBD is to become a valid and useful system for determining health priorities.

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. Publishing Authors By Initials

CH King,AM Bertino,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: PLoS neglected tropical diseases

VOLUME: 2

Page Numbers: e209

Journal Abbreviation: PLoS Negl Trop Dis

ISSN: 1935-2735

DAY: 26

MONTH: 03

YEAR: 2008

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101291488

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases.

AFFILIATION: Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: PLoS Negl Trop Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases Related Publications

• A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance.
• Absorption of leucovorin (NSC-3590) from a "mouthwash".
• Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases.
• Chemotherapeutic approaches to advanced carcinoma of the larynx.
• Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors.
• Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma.
• Failure of leucovorin "rescue" in methotrexate treatment of psoriasis.
• Head and neck cancer. 3. Toxicity of 24-hour infusions of methotrexate (NSC-740) and protection by leucovorin (NSC-3590) in patients with epidermoid carcinomas.
• Implantable pump for long-term chemotherapy administration via the hepatic artery: has it fulfilled its promise?
• In vitro reconstructed normal human epidermis expresses differentiation-related proteoglycans.
• Methotrexate (NSC-740) in squamous cell carcinoma of the head and neck. II. Intermittent intravenous therapy.
• MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics.
• Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment.
• Pharmacodynamics of Uniform versus Nonuniform Warfarin Dosages.
• Preclinical studies with triazinate (NSC-139105), an antifolate drug, in beagle dogs and rhesus monkeys.
• Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA.
• Recent developments in chemotherapy of malignancy.
• Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease.
• The journal of clinical oncology: the initial years.
• Treatment of advanced neoplastic disease with 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037).
• [Not Available.]